400 related articles for article (PubMed ID: 22089927)
1. Cancer and altered metabolism: potential importance of hypoxia-inducible factor and 2-oxoglutarate-dependent dioxygenases.
Kaelin WG
Cold Spring Harb Symp Quant Biol; 2011; 76():335-45. PubMed ID: 22089927
[TBL] [Abstract][Full Text] [Related]
2. Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation.
Koivunen P; Lee S; Duncan CG; Lopez G; Lu G; Ramkissoon S; Losman JA; Joensuu P; Bergmann U; Gross S; Travins J; Weiss S; Looper R; Ligon KL; Verhaak RG; Yan H; Kaelin WG
Nature; 2012 Feb; 483(7390):484-8. PubMed ID: 22343896
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of α-KG-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors.
Xiao M; Yang H; Xu W; Ma S; Lin H; Zhu H; Liu L; Liu Y; Yang C; Xu Y; Zhao S; Ye D; Xiong Y; Guan KL
Genes Dev; 2012 Jun; 26(12):1326-38. PubMed ID: 22677546
[TBL] [Abstract][Full Text] [Related]
4. 2-Oxoglutarate-dependent dioxygenases in cancer.
Losman JA; Koivunen P; Kaelin WG
Nat Rev Cancer; 2020 Dec; 20(12):710-726. PubMed ID: 33087883
[TBL] [Abstract][Full Text] [Related]
5. The multifaceted role of EGLN family prolyl hydroxylases in cancer: going beyond HIF regulation.
Strocchi S; Reggiani F; Gobbi G; Ciarrocchi A; Sancisi V
Oncogene; 2022 Jul; 41(29):3665-3679. PubMed ID: 35705735
[TBL] [Abstract][Full Text] [Related]
6. Neuronal apoptosis by prolyl hydroxylation: implication in nervous system tumours and the Warburg conundrum.
Schlisio S
J Cell Mol Med; 2009 Oct; 13(10):4104-12. PubMed ID: 19691672
[TBL] [Abstract][Full Text] [Related]
7. Enzyme substrate recognition in oxygen sensing: how the HIF trap snaps.
Metzen E
Biochem J; 2007 Dec; 408(2):e5-6. PubMed ID: 17990984
[TBL] [Abstract][Full Text] [Related]
8. The von Hippel Lindau/hypoxia-inducible factor (HIF) pathway regulates the transcription of the HIF-proline hydroxylase genes in response to low oxygen.
del Peso L; Castellanos MC; Temes E; Martin-Puig S; Cuevas Y; Olmos G; Landazuri MO
J Biol Chem; 2003 Dec; 278(49):48690-5. PubMed ID: 14506252
[TBL] [Abstract][Full Text] [Related]
9. Endogenous 2-oxoglutarate levels impact potencies of competitive HIF prolyl hydroxylase inhibitors.
Thirstrup K; Christensen S; Møller HA; Ritzén A; Bergström AL; Sager TN; Jensen HS
Pharmacol Res; 2011 Sep; 64(3):268-73. PubMed ID: 21504793
[TBL] [Abstract][Full Text] [Related]
10. Fumarate and Succinate Regulate Expression of Hypoxia-inducible Genes via TET Enzymes.
Laukka T; Mariani CJ; Ihantola T; Cao JZ; Hokkanen J; Kaelin WG; Godley LA; Koivunen P
J Biol Chem; 2016 Feb; 291(8):4256-65. PubMed ID: 26703470
[TBL] [Abstract][Full Text] [Related]
11. HIF prolyl hydroxylase-3 mediates alpha-ketoglutarate-induced apoptosis and tumor suppression.
Tennant DA; Gottlieb E
J Mol Med (Berl); 2010 Aug; 88(8):839-49. PubMed ID: 20383689
[TBL] [Abstract][Full Text] [Related]
12. Iron chelation and 2-oxoglutarate-dependent dioxygenase inhibition suppress mantle cell lymphoma's cyclin D1.
Babosova O; Kapralova K; Raskova Kafkova L; Korinek V; Divoky V; Prchal JT; Lanikova L
J Cell Mol Med; 2019 Nov; 23(11):7785-7795. PubMed ID: 31517438
[TBL] [Abstract][Full Text] [Related]
13. Rare insights into cancer biology.
Adam J; Yang M; Soga T; Pollard PJ
Oncogene; 2014 May; 33(20):2547-56. PubMed ID: 23812428
[TBL] [Abstract][Full Text] [Related]
14. New cancer targets emerging from studies of the Von Hippel-Lindau tumor suppressor protein.
Kaelin WG
Ann N Y Acad Sci; 2010 Oct; 1210():1-7. PubMed ID: 20973793
[TBL] [Abstract][Full Text] [Related]
15. The EGLN-HIF O
Ivan M; Kaelin WG
Mol Cell; 2017 Jun; 66(6):772-779. PubMed ID: 28622522
[TBL] [Abstract][Full Text] [Related]
16. BCAT1 restricts αKG levels in AML stem cells leading to IDHmut-like DNA hypermethylation.
Raffel S; Falcone M; Kneisel N; Hansson J; Wang W; Lutz C; Bullinger L; Poschet G; Nonnenmacher Y; Barnert A; Bahr C; Zeisberger P; Przybylla A; Sohn M; Tönjes M; Erez A; Adler L; Jensen P; Scholl C; Fröhling S; Cocciardi S; Wuchter P; Thiede C; Flörcken A; Westermann J; Ehninger G; Lichter P; Hiller K; Hell R; Herrmann C; Ho AD; Krijgsveld J; Radlwimmer B; Trumpp A
Nature; 2017 Nov; 551(7680):384-388. PubMed ID: 29144447
[TBL] [Abstract][Full Text] [Related]
17. The balance of beneficial and deleterious effects of hypoxia-inducible factor activation by prolyl hydroxylase inhibitor in rat remnant kidney depends on the timing of administration.
Yu X; Fang Y; Liu H; Zhu J; Zou J; Xu X; Jiang S; Ding X
Nephrol Dial Transplant; 2012 Aug; 27(8):3110-9. PubMed ID: 22399494
[TBL] [Abstract][Full Text] [Related]
18. Mouse model for noninvasive imaging of HIF prolyl hydroxylase activity: assessment of an oral agent that stimulates erythropoietin production.
Safran M; Kim WY; O'Connell F; Flippin L; Günzler V; Horner JW; Depinho RA; Kaelin WG
Proc Natl Acad Sci U S A; 2006 Jan; 103(1):105-10. PubMed ID: 16373502
[TBL] [Abstract][Full Text] [Related]
19. A yeast three-hybrid system that reconstitutes mammalian hypoxia inducible factor regulatory machinery.
Alcaide-German ML; Vara-Vega A; Garcia-Fernandez LF; Landazuri MO; del Peso L
BMC Cell Biol; 2008 Apr; 9():18. PubMed ID: 18402654
[TBL] [Abstract][Full Text] [Related]
20. Prolyl hydroxylases 2 and 3 act in gliomas as protective negative feedback regulators of hypoxia-inducible factors.
Henze AT; Riedel J; Diem T; Wenner J; Flamme I; Pouyseggur J; Plate KH; Acker T
Cancer Res; 2010 Jan; 70(1):357-66. PubMed ID: 20028863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
